Esteve

Spain - BarcelonaBiotechnology1 H-1B visas (FY2023)

Focus: Esteve is a Barcelona-based biotechnology company specializing in small molecules and gene therapy, with a legacy portfolio anchored by niche endocrinology and pain management drugs. The company operates as a specialty biotech with significant revenue concentration in legacy assets facing near-term patent expiration.

Gene Therapy

Profile data last refreshed 13h ago · AI intelligence enriched 2w ago

Open Jobs

About Esteve

AI assessmentNot Hiring

No open roles listed right now. Follow Esteve to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

LYSODREN

Adrenocortical carcinoma

$2M Part D

LOE Approaching

Flagship revenue driver (68% of total) facing near-term patent expiration with no disclosed successor strategy.

Help build intelligence for Esteve

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to rare disease and specialty pharma segments (adrenal and neuroendocrine disorders) with established commercial infrastructure and reimbursement pathways
Pipeline diversity across pain management, respiratory, and oncology with two Phase 3 programs (E-58425, Calcium Dobesilate) offering near-term clinical catalysts
European biotech base with demonstrated H1B sponsorship (1 approval, 0 denials in 2023) providing visa-sponsoring flexibility for US-bound roles

Watch Out For

Severe revenue concentration risk: 68% of revenue from LYSODREN (mitotane), which is LOE-approaching, with no disclosed loss-of-exclusivity date or succession strategy
Pipeline early-stage and fragmented: only 2 Phase 3 programs and 1 Phase 2 out of 10 programs listed, with most lacking active trial counts—indicative of early discovery or partnered assets with limited internal development momentum
No active job openings (0 listed) and no published hiring plan; limited transparency on scale (employee count not disclosed) suggests constrained near-term career entry points

Pipeline & Clinical Trials

Ziconotide [Prialt]

Pain, Chronic

N/A

Clinical Trials (1)

NCT06541184Ziconotide for Non-cancer Pain by Intrathecal Administration

N/A

Aquoral Lipo

Contact Lens Complication

N/A

Clinical Trials (1)

NCT05290727Efficacy of "Aquoral Lipo" Artificial Tears in Contact Lens Wearers With Discomfort

N/A

Ziconotide Injection

Refractory Pain

N/A

Clinical Trials (1)

NCT04321408OP2C : Prialt® Observatory in Clinical Practice

N/A

Increlex®

IGF1 Deficiency

N/A

Clinical Trials (1)

NCT00903110Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

N/A

budesonide-formoterol single inhaler

Bronchiectasis

N/A

Clinical Trials (1)

NCT00728715Efficacy of Budesonide-Formoterol in Bronchiectasis

N/A

Scientific writing training course

Scientific Writing Training Course

N/A

Clinical Trials (1)

NCT05798598Evaluation of Competencies in Scientific Writing and Attendees' Satisfaction After Two Different Types of Training Courses: SCRIU-B Study

N/A

Translational Research in Pelvic Pain

Endometriosis

N/A

Cyclophosphamide

Multiple Myeloma

Phase 2

Clinical Trials (1)

NCT03700450Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma

Phase 2

Calcium Dobesilate

Ulcer

Phase 3

Clinical Trials (1)

NCT00979836Calcium Dobesilate for Chronic Venous Wounds

Phase 3

Co-crystal E-58425

Acute Post-surgical Pain

Phase 3

Clinical Trials (1)

NCT03108482Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.

Phase 3

Interview Prep Quick Facts

Founded: 1996

Portfolio: 2 approved products, 9 clinical trials

Top TAs: Endocrinology, Nephrology, Psychiatry

H-1B (2023): 1 approval

Portfolio Health

LOE Approaching2 (100%)

2 total products

Therapeutic Area Focus

1 marketed

1 marketed

1 marketed

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 3 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Esteve

About Esteve

Why Work Here

Key Products

Watch Out For

Products & Portfolio (2)

Key Products by Revenue

Pipeline & Clinical Trials

Open Jobs (0)

Hiring Trend

Visa Sponsorship